Health Care & Life Sciences » Medical Equipment & Supplies | Oculus Innovative Sciences Inc.

Oculus Innovative Sciences Inc. | Cash Flow

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
3,735.00
8,203.00
10,162.00
9,274.00
14,328.00
Depreciation, Depletion & Amortization
284.00
253.00
244.00
248.00
490.00
Other Funds
8,577.00
3,438.00
2,834.00
17,432.00
3,151.00
Funds from Operations
4,558.00
4,512.00
7,084.00
7,910.00
10,687.00
Changes in Working Capital
332.00
2,182.00
1,662.00
257.00
1,752.00
Net Operating Cash Flow
4,890.00
6,694.00
8,746.00
8,167.00
12,439.00
Capital Expenditures
504.00
139.00
345.00
394.00
187.00
Purchase/Sale of Investments
-
963.00
4,538.00
-
-
Net Investing Cash Flow
445.00
875.00
4,191.00
18,224.00
201.00
Issuance/Reduction of Debt, Net
1,538.00
176.00
119.00
130.00
280.00
Net Financing Cash Flow
2,945.00
6,609.00
6,039.00
32.00
5,240.00
Net Change in Cash
2,420.00
656.00
1,333.00
9,992.00
7,395.00
Free Cash Flow
5,394.00
6,833.00
9,091.00
8,561.00
12,626.00
Other Sources
-
51.00
-
18,639.00
-
Change in Capital Stock
4,483.00
6,785.00
6,158.00
98.00
5,520.00
Exchange Rate Effect
30.00
134.00
151.00
33.00
5.00
Other Uses
59.00
-
2.00
21.00
14.00

About Oculus Innovative Sciences

View Profile
Address
1129 North McDowell Boulevard
Petaluma California 94954
United States
Employees -
Website http://www.sonomapharma.com
Updated 09/14/2018
Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. It offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.